AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
SAN FRANCISCO, July 25, 2017 -- Hagens Berman Sobol Shapiro LLP reminds investors in Mazor Robotics Ltd. (NASDAQ:MZOR) of the August 8, 2017 Lead Plaintiff deadline in the pending securities class action.
If you purchased or otherwise acquired securities of MZOR between November 8, 2016 and June 8, 2017 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/MZOR
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On June 8, 2017, Mazor announced that in May 2017 the Israeli Securities Authority (“ISA”) searched Mazor’s offices and questioned certain officers in connection with an investigation held by the ISA. This news drove the price of Mazor’s ADRs down almost 10% to close at $33.67 that day. On June 9, 2017 the price of Mazor’s ADRs fell another 9.1% to close at $30.59 on June 9, 2017.
“We’re focused on events as they unfold and certainly on whether Mazor engaged in improper accounting that triggered the ISA’s search,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding MZOR should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
